131 related articles for article (PubMed ID: 36706944)
1. Contribution of the Interferon score in the management of an anti-NXP2 dermatomyositis patient with calcinosis successfully treated with tofacitinib.
Robert M; Gallay L; Garnier L; Pescarmona R; Hot A
Joint Bone Spine; 2023 Jul; 90(4):105532. PubMed ID: 36706944
[No Abstract] [Full Text] [Related]
2. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Wendel S; Venhoff N; Frye BC; May AM; Agarwal P; Rizzi M; Voll RE; Thiel J
J Autoimmun; 2019 Jun; 100():131-136. PubMed ID: 30862449
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory anti-NXP2 and anti-TIF1γ dermatomyositis with tofacitinib.
Navarro-Navarro I; Jiménez-Gallo D; Rodríguez-Mateos ME; Rodríguez-Hernández C; Linares-Barrios M
J Dtsch Dermatol Ges; 2021 Mar; 19(3):443-447. PubMed ID: 32909360
[No Abstract] [Full Text] [Related]
5. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate.
Sözeri B; Demir F
Rheumatology (Oxford); 2020 Dec; 59(12):e140-e141. PubMed ID: 32754736
[No Abstract] [Full Text] [Related]
6. Universalis Calcinosis in Adult Dermatomyositis: An "Anti-NXP2 Syndrome".
Fodil D; Meyer A; Salah SS; Sibilia J; Attal N; Tafiani-Lefkir S
J Clin Rheumatol; 2016 Oct; 22(7):387-9. PubMed ID: 27660942
[No Abstract] [Full Text] [Related]
7. Regression of cutis calcinosis with diltiazem in adult dermatomyositis.
Abdallah-Lotf M; Grasland A; Vinceneux P; Sigal-Grinberg M
Eur J Dermatol; 2005; 15(2):102-4. PubMed ID: 15757822
[TBL] [Abstract][Full Text] [Related]
8. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series.
Shneyderman M; Ahlawat S; Christopher-Stine L; Paik JJ
Rheumatology (Oxford); 2021 Nov; 60(11):e387-e388. PubMed ID: 33961025
[No Abstract] [Full Text] [Related]
9. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment.
Nakagawa T; Takaiwa T
J Dermatol; 1993 Sep; 20(9):558-60. PubMed ID: 8227711
[TBL] [Abstract][Full Text] [Related]
10. Treatment With Rituximab in Juvenile Dermatomyositis: Effect on Calcinosis.
Vargas Lebrón C; Ruiz Montesino MD; Moreira Navarrete V; Toyos Sainz de Miera FJ
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):368-370. PubMed ID: 30054253
[No Abstract] [Full Text] [Related]
11. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.
Takanashi S; Kaneko Y; Takeuchi T
Mod Rheumatol; 2022 Jan; 32(1):231-237. PubMed ID: 33769925
[No Abstract] [Full Text] [Related]
12. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.
Takatani A; Koga T; Fujita Y; Fukui S; Endo Y; Shimizu T; Kawakami A
Clin Immunol; 2020 Jun; 215():108451. PubMed ID: 32360518
[No Abstract] [Full Text] [Related]
13. Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis.
Martillotti J; Moote D; Zemel L
Pediatr Radiol; 2014 Jan; 44(1):115-8. PubMed ID: 23839717
[TBL] [Abstract][Full Text] [Related]
14. Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.
Xue Y; Zhang J; Deng J; Kuang W; Wang J; Tan X; Li C; Li S; Li C
Ann Rheum Dis; 2023 Nov; 82(11):1499-1501. PubMed ID: 37280048
[No Abstract] [Full Text] [Related]
15. Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.
Luo M; Chen L; He H; He F
Eur J Med Res; 2022 May; 27(1):68. PubMed ID: 35570320
[TBL] [Abstract][Full Text] [Related]
16. Calcinosis in childhood dermatomyositis.
Martínez-Cordero E; López-Zepeda J; Choza-Romero F
Clin Exp Rheumatol; 1990; 8(2):198-200. PubMed ID: 2338016
[No Abstract] [Full Text] [Related]
17. Scintigraphic evaluation of calcinosis in juvenile dermatomyositis with Tc-99m MDP.
Bar-Sever Z; Mukamel M; Harel L; Hardoff R
Clin Nucl Med; 2000 Dec; 25(12):1013-6. PubMed ID: 11129136
[TBL] [Abstract][Full Text] [Related]
18. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin.
Peñate Y; Guillermo N; Melwani P; Martel R; Hernández-Machín B; Borrego L
J Am Acad Dermatol; 2009 Jun; 60(6):1076-7. PubMed ID: 19467386
[No Abstract] [Full Text] [Related]
19. Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.
Fu Y; Gu L; Chen J; Dai Y; Feng Q; Chen Z; Fan J; Gao M; Wang X; Fu Q; Ye S
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199847
[TBL] [Abstract][Full Text] [Related]
20. Anti-NXP2 antibody-associated extensive subcutaneous calcinosis in adult-onset myositis.
Goulabchand R; Guilpain P; Cyteval C; Le Quellec A
Rheumatology (Oxford); 2017 Oct; 56(10):1661. PubMed ID: 28605526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
